ImmunoGen, Inc. is a pioneering biotechnology company dedicated to revolutionizing cancer treatment through cutting-edge antibody-drug conjugate (ADC) technology. Targeting a better future for cancer patients, ImmunoGen's mission is to not only disrupt cancer's progression but also ensure that it does not disrupt the quality of life. With over 40 years of expertise in developing ADCs, ImmunoGen has been at the forefront of research to create more effective and well-tolerated anti-cancer therapies. Through their innovative approach, they aim to provide patients with fewer interruptions and more good days.

Their commitment to patients is exemplified through inspiring stories like Jess, Donna, and Nick, who have overcome various forms of cancer with the help of ImmunoGen's advancements. By leveraging the targeting abilities of antibodies to deliver drugs directly to cancer cells, ImmunoGen continues to lead the way in advancing cancer treatment. Join them in targeting a better now and shaping a brighter future for cancer care.